- Home
- AUPH vs NFJ Comparison
AUPH vs NFJ Comparison
Compare AUPH & NFJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUPH | NFJ |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUPH | NFJ |
|---|---|---|
| Price | $14.34 | $12.97 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 857.6K | 163.9K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.01% |
| EPS Growth | ★ 5075.00 | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $283,055,000.00 | N/A |
| Revenue This Year | $17.35 | N/A |
| Revenue Next Year | $15.66 | N/A |
| P/E Ratio | $7.11 | ★ N/A |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $6.83 | $10.02 |
| 52 Week High | $16.54 | $13.92 |
Technical Indicators
Market Signals| Indicator | AUPH | NFJ |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 29.46 |
| Support Level | $13.52 | $12.62 |
| Resistance Level | $16.28 | $13.21 |
| Average True Range (ATR) | 0.54 | 0.20 |
| MACD | 0.05 | -0.09 |
| Stochastic Oscillator | 46.51 | 2.49 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.